Showing 501-510 of 1560 results for "".
Curing Blindness: How Researchers are Utilizing Gene Therapy
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/curing-blindness-how-researchers-are-utilizing-gene-therapy/8450/Dr. Jean Bennett discusses her innovative work and research in curing blindness through gene therapy.Time is Brain: Diagnosing and Treating Stroke in the Golden Window
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/time-is-brain-diagnosing-and-treating-stroke-golden-window/8216/Dr. Michael Mullen overviews the clinical hallmarks and priority treatment consideration for stroke.From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
https://reachmd.com/programs/project-oncology/from-mgus-to-multiple-myeloma-understanding-the-progression-of-precursor-diseases/26584/Tune in to learn about precursor diseases and how they eventually progress to multiple myeloma.Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
https://reachmd.com/programs/neurofrontiers/epigenetic-immune-signatures-in-alzheimers-implications-for-diagnosis-and-therapy/36464/Patients with Alzheimer's disease—especially APOE4 carriers—show distinct epigenetic immune alterations that may influence disease progression, treatment response, and side effect risk. In this episode, Dr. David Gate, an Assistant Professor of Behavioral Neurology at Northwestern University, divesGene-Editing: The Potential Key to Eliminating HIV
https://reachmd.com/programs/clinicians-roundtable/gene-editing-the-potential-key-to-eliminating-hiv/15744/Scientists are one step closer to a cure for HIV. Here’s what we know about their recently discovered gene-editing strategy to eliminate the virus.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaThe Aryl Hydrocarbon Receptor and Lupus: Diagnostic and Therapeutic Advancements
https://reachmd.com/programs/living-rheum/the-aryl-hydrocarbon-receptor-and-lupus-diagnostic-and-therapeutic-advancements/28634/Explore the connection between the aryl hydrocarbon receptor and systemic lupus erythematosus and uncover its potential to improve treatment options.Career Choices Under the Microscope: Research Medicine
https://reachmd.com/programs/your-career-in-healthcare/career-choices-under-the-microscope-research-medicine/6523/Dr. Aimee Payne is assistant director of the medical scientist training program at the University of Pennsylvania and the core director of the Penn Skin Disease Research Center, where she focuses on the autoimmune blistering disease pemphigus vulgaris, a potentially fatal disorder in which autoantibEfgartigimod Shows Early Promise for Primary Sjögren’s Disease
https://reachmd.com/programs/living-rheum/efgartigimod-shows-early-promise-for-primary-sjogrens-disease/36333/Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
https://reachmd.com/programs/project-oncology/androgen-receptor-emerges-as-a-marker-of-differentiation-in-endometrial-cancer/35511/Read about emerging data positioning the androgen receptor as a complementary biomarker for stratifying hormone-responsive endometrial cancer.